Trial Profile
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Tuberous sclerosis
- Focus Adverse reactions
- 01 Sep 2020 Status changed from recruiting to completed.
- 11 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 11 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2020.